Viracta Therapeutics (VIRX)
(Delayed Data from NSDQ)
$0.22 USD
0.00 (-0.23%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $0.22 0.00 (0.23%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Viracta (VIRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.50 | $4.00 | $3.00 | 1,490.91% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Viracta comes to $3.50. The forecasts range from a low of $3.00 to a high of $4.00. The average price target represents an increase of 1% from the last closing price of $0.22.
Analyst Price Targets (2 )
Broker Rating
Viracta currently has an average brokerage recommendation (ABR) of 2.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on three recommendations.
Of the two recommendations deriving the current ABR, one is Buy, representing 50% of all recommendations. A month ago, Strong Buy made up 33.33%, while Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 1 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.50 | 2.50 | 2.00 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/16/2024 | SVB Securities | Andrew Berens | Hold | Hold |
8/15/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.50 |
ABR (Last week) | 2.50 |
# of Recs in ABR | 2 |
Average Target Price | $3.50 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 74 of 253 |
Current Quarter EPS Est: | -0.21 |
VIRX FAQs
Viracta Therapeutics, Inc. (VIRX) currently has an average brokerage recommendation (ABR) of 2.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 2 brokerage firms.
The average price target for Viracta Therapeutics, Inc. (VIRX) is $3.50. The current on short-term price targets is based on 1 reports.
The forecasts for Viracta Therapeutics, Inc. (VIRX) range from a low of $3 to a high of $4. The average price target represents a increase of $1490.91 from the last closing price of $.22.
The current UPSIDE for Viracta Therapeutics, Inc. (VIRX) is 1490.91%
Based on short-term price targets offered by two analysts, the average price target for Viracta comes to $3.50. The forecasts range from a low of $3.00 to a high of $4.00. The average price target represents an increase of 1% from the last closing price of $0.22.